688526 Wuhan Keqian Biology Co.,Ltd
- 18.29
- -0.36-1.93%
Wuhan Keqian Biology Co.,Ltd News
Keqian Biotech (688526.SH): A total of 1.4812 million shares of the company have been repurchased
Gelonghui, May 6 | Keqian Biotech (688526.SH) announced that as of April 30, 2024, the company had repurchased 1,481,214 shares of the company's shares through centralized bidding transactions, accounting for 0.3177% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.64 yuan/share, the lowest price was 16.22 yuan/share, and the total amount of capital paid was RMB 24,372,261.54 (excluding transaction fees such as stamp duty and transaction fees).
Ke Qian Biology (688526): Overall performance is under pressure and waiting for demand to pick up in the post-cycle
The downturn in the downstream farming sector has temporarily put pressure on the company's performance, and the overall risk of accounts receivable is manageable. The rise in 24H2 pig prices may drive demand for sports insurance to reach an upward inflection point, and the inflection point in the company's performance is getting closer. In addition, major single products such as the non-plague vaccine & cat trifecta
Keqian Biology (688526): Demand pressure is dragging down performance and is expected to take the lead in benefiting from rising pig prices
The 1Q24 performance is in line with our expectations, and Keqian Biotech announced 1Q24 results: the company achieved revenue of 205 million yuan, -26.7% year over year, net profit attributable to mother was 87 million yuan, or -35.6% year over year, deducted
Ke Qian Biology (688526): Downstream sluggish performance is temporarily under pressure, research reserves are abundant, and growth can be expected
Event: The company's 2023 revenue +6.27%, net profit to mother -3.32%; 2024Q1 revenue -26.7%, net profit to mother -35.6%. The company's 2023 annual report achieved operating income of 10.64
Keqian Biotech (688526.SH): Net profit of 87.228 million yuan in the first quarter decreased 35.64% year-on-year
On April 29, Ge Longhui Biotech (688526.SH) released its first quarter report. Operating revenue was 200 million yuan, down 26.68% year on year, net profit was 87.228 million yuan, down 35.64% year on year, after deducting non-net profit of 76.1578 million yuan, down 40.56% year on year, with basic earnings of 0.18 yuan per share.
Keqian Biology (688526) First Coverage Report: Product Strength+R&D Strength Building Core Competitiveness of Leading Companies Without Forced Exemption of Pig Seedlings
In the short term, as 24H2 pig prices enter an upward cycle, demand for animal insurance is expected to pick up. Pig prices have continued to be low since 23 years, and the downstream pig farming industry has been in losses for 15 consecutive months. The triple impact of financial pressure, pessimistic expectations, and the epidemic
Ke Qian Biology (688526): Year-on-year decline in profit, waiting for post-cycle sentiment to recover
Continued downstream losses led to year-on-year pressure on Q1's performance. Maintaining a “buy” rating, Keqian Biotech released a quarterly report. In 2024, Q1 achieved revenue of 205 million yuan (yoy -26.68%, qoq -13.40%), which returned
Southwest Securities released a research report on April 11 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) comments: pig vaccines drive revenue growth, and depreciation affects profits; 2) pr
Southwest Securities released a research report on April 11 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) comments: pig vaccines drive revenue growth, and depreciation affects profits; 2) promote technological innovation to build the company's core competitiveness; 3) production capacity on the breeding side continues to decline, and cycle reversal drives volume and price increases in the sports insurance sector. (Mainichi Keizai Shimbun)
SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging
SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging down profit levels; 2) the main pig breeding business is stable, and the poultry seedlings business continues to expand; 3) R&D lays the future, and there are sufficient reserves of new products. (Mainichi Keizai Shimbun)
Keqian Biology (688526): Swine vaccine drives revenue growth, increases impairment and affects profits
Performance summary: The company released its 2023 annual report. In 2023, the company achieved revenue of 1,064 billion yuan, +6.27% year-on-year, and realized net profit to mother of 396 million yuan, -3.32% year-on-year. which
Keqian Biotech (688526) 2023 Report Review: Credit impairment dragged down Q4's net profit to mother decreased by about 70% year-on-year
The gross margin of the main business was under pressure, and large credit impairment confirmed that the company's net profit to the mother decreased by 3% year-on-year in 2023. The company achieved revenue of 1,064 billion yuan in 2023, +6.27% year-on-year, mainly due to the company strengthening market development
Guoxin Securities released a research report on April 8 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) gross margin of pig vaccines is under pressure, and the pet vaccine business volume is i
Guoxin Securities released a research report on April 8 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) gross margin of pig vaccines is under pressure, and the pet vaccine business volume is increasing; 2) net interest rates are under pressure but cost ratios have been optimized; 3) net operating cash flow has remained stable, and the number of accounts receivable turnover days has increased. (Mainichi Keizai Shimbun)
Keqian Biology (688526): Depreciation drags down performance, focus on the new product launch process
Incident: The company announced its 2023 annual report. The company achieved a total operating income of 1,064 million yuan, yoy 6.27%, and net profit to mother of 395 million yuan, yoy -3.32% for the full year of 2023. A small amount of revenue
Keqian Biotech (688526) 2023 Report Review: Steady operation of core single products, depreciation in the fourth quarter dragged down performance, waiting for the cycle to reverse
Matters: The company disclosed its 2023 annual report. It achieved full-year revenue of 1,064 billion yuan, a year-on-year increase of 6.27%, net profit to mother of 396 million yuan, a year-on-year decrease of 3.32%, and net profit of 371 million yuan after deducting non-return to mother net profit of 371 million yuan, year-on-year decline
Keqian Biology (688526) Company Information Update Report: The implementation of various new products will immediately benefit pig cycle reversal and promotion of anti-plague vaccines
A number of new products are being implemented soon, benefiting from the reversal of the pig cycle and the promotion of anti-plague vaccines. Maintaining the “Buy” rating, the company published its 2023 annual report. In 2023, it achieved revenue of 1,064 billion yuan, yoy +6.27%, and net profit of 3 to the mother
Keqian Biology (688526) 2023 Annual Report Review: Depreciation Drags Down Performance, R&D Innovation Entering the Harvest Period
Event: On April 1, 2024, Keqian Biotech released its 2023 annual report: in 2023, the company achieved operating income of 1,064 billion yuan, +6.27% year-on-year, and net profit to mother of 396 million yuan, year-on-year.
Express News | The Social Security Fund appeared on the list of the top ten tradable shareholders of 22 science and technology innovation board stocks
Keqian Biotech (688526.SH): A total cost of 24.37 million yuan to buy back 0.3177% of the shares
Gelonghui, April 1 | Keqian Biotech (688526.SH) announced that as of March 31, 2024, the company had repurchased 1,481,214 shares of the company's shares through centralized bidding transactions, accounting for 0.3177% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.64 yuan/share, the lowest price was 16.22 yuan/share, and the total amount of capital paid was RMB 24,372,261.54 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Keqian Biology: Net profit in 2023 fell 3.32% year on year, and plans to pay 10 to 4.3 yuan
Keqian Biology (688526): Credit impairment is dragging down profits, waiting for an inflection point in performance
Credit impairment dragged down the company's profit for 23 years. The rise in 24H2 pig prices may drive demand for sports insurance to an upward inflection point, and the inflection point in the company's performance is getting closer. In addition, commercialization of major single products such as the anti-plague vaccine & cat trifecta may open up room for growth for the company. upholding
Analysis
Price Target
No Data
